Med24
peptide-development 31. 8. 2026 • 2 min read • JCEM case reports

Tirzepatide non-response with subsequent semaglutide response in class 2 obesity

We report a paradoxical case of a 40-year-old man with class 2 obesity (body mass index 39.8 kg/m 2 ) and insulin resistance (homeostatic model assessment of insulin resistance [HOMA-IR] 5.0; reference

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

A 40-year-old man with class 2 obesity (body mass index 39.8 kg/m2) and insulin resistance (HOMA-IR 5.0) initially responded minimally to tirzepatide, achieving less than 5% weight loss despite escalating the weekly dose to 15 mg. The patient’s insulin resistance was characterized by a high HOMA-IR value.

Key Clinical Findings

Following a switch to semaglutide at 2.4 mg weekly, the patient experienced a 20% weight loss over six months. This transition was accompanied by normalization of fasting glucose levels and a significant improvement in appetite control. Analysis suggests that adipose tissue GIP receptor downregulation, potentially linked to class 2 obesity and insulin resistance, may contribute to differing responses to dual GIP/GLP-1 receptor agonists. The study highlights the potential for intact central GLP-1 receptor signaling to influence treatment outcomes. The case emphasizes the importance of considering individual patient characteristics, such as insulin resistance, when selecting obesity pharmacotherapy.

Sponsored content

Important Considerations

Key learning points include the association of markedly elevated baseline insulin resistance (HOMA-IR ≥4-5) with a potential poor response to tirzepatide. Persistent hyperphagia during tirzepatide treatment serves as an early indicator of non-response. Furthermore, a nonresponse to tirzepatide does not necessarily preclude a response to semaglutide.”

Original Scientific Source
JCEM case reports
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
peptide-development

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight...

1. 12. 2026 Read article →
Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation
peptide-development

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits...

10. 11. 2026 Read article →
The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome
peptide-development

The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome

Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and...

23. 10. 2026 Read article →
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
peptide-development

Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review

Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence...

16. 10. 2026 Read article →
Advertisement